Key result
Trophic and stem-cell therapies promote preclinical stroke repair, though clinical efficacy remains unproven.
Brain repair involves a compendium of natural mechanisms that are activated following stroke. From a therapeutic viewpoint, reparative therapies that encourage cerebral plasticity are needed. In the last years, it has been demonstrated that modulatory treatments for brain repair such as trophic factor- and stem cell-based therapies can promote neurogenesis, gliogenesis, oligodendrogenesis, synaptogenesis and angiogenesis, all of which having a beneficial impact on infarct volume, cell death and, finally, and most importantly, on the functional recovery. However, even when promising results have been obtained in a wide range of experimental animal models and conditions these preliminary results have not yet demonstrated their clinical efficacy. Here, we focus on brain repair modulatory treatments for ischaemic stroke, that use trophic factors, drugs with trophic effects and stem cell therapy. Important and still unanswered questions for translational research ranging from experimental animal models to recent and ongoing clinical trials are reviewed here.
No takes yet. Share an insight, caveat, or question.
Gutiérrez‐Fernández et al. (2012) conducted a review in Ischaemic stroke. Trophic factors, drugs with trophic effects, and stem cell therapy was evaluated on Brain repair and functional recovery. Trophic factor- and stem cell-based therapies promote neurogenesis and angiogenesis in experimental stroke models, though clinical efficacy has not yet been demonstrated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: